PTSD treatment limitations and novel pharmacotherapy approaches to transform standard of care

[Available On-Demand]
Search General Info
Search Education
Search Partnering Companies
Bring a team of behavioral/neurobiology, neuroepigeneticists, and psychiatry clinician to discuss the growing, dire straits of PTSD patients; and discuss novel pharmacotherapy approaches through neuroepigenetics.
Rachel Yehuda, PhD (Mount Sinai) will provide background on the standard of care, and the limitations of such therapies, and then discuss the need for new therapeutic approaches to help the growing population of PTSD patients.
Marcelo Wood, PhD (UC Irvine) will discuss epigenetic approaches, and improving behavioral animal models to test these thesis with more confidence in their correlation to PTSD.
Philipp Mews, PhD (cofounder EpiVario Inc) will then discuss findings that a metabolic enzyme can control stress reconsolidation through epigenetic regulation, supported through rodent stress model data. Suggesting treating patients in an augmented regimen, which works by inhibiting stress reconsolidation to reduce the level of stress response to trauma memory reactivation.
Moderator
photo
President & CEO
EpiVario Inc.
Speakers
photo
President & CEO
EpiVario Inc.
photo
Cofounder
EpiVario Inc.
photo
Professor
University California Irvine
photo
Director of the Traumatic Stress Studies Division, Professor of Psychiatry and Neuroscience
Mount Sinai School of Medicine